gene-disease association extraction
**Gene-Disease Association Extraction** is the **biomedical NLP task of automatically identifying relationships between genes, genetic variants, and human diseases from scientific literature** — populating the knowledge bases that drive Mendelian disease gene discovery, polygenic risk score construction, cancer driver identification, and precision medicine by extracting the genetic-disease links documented across millions of biomedical publications.
**What Is Gene-Disease Association Extraction?**
- **Task Definition**: Relation extraction identifying (Gene/Variant, Disease, Association Type) triples from biomedical text.
- **Association Types**: Causal (gene mutation causes disease), risk (variant increases susceptibility), therapeutic target (gene modulation treats disease), biomarker (gene expression indicates disease state), complication (disease causes gene dysregulation).
- **Key Databases Populated**: DisGeNET (1.1M gene-disease associations), OMIM (Mendelian genetics), ClinVar (variant-disease clinical significance), COSMIC (cancer somatic mutations), PharmGKB (pharmacogenomics).
- **Key Benchmarks**: BC4CHEMD (chemical-gene), BioRED (multi-entity relation), NCBI Disease Corpus, CRAFT Corpus.
**The Association Extraction Challenge**
Gene-disease associations in literature come in many forms:
**Direct Causal Statement**: "Mutations in CFTR cause cystic fibrosis." → (CFTR gene, Cystic Fibrosis, Causal).
**Statistical Association**: "The rs12913832 SNP in OCA2 is associated with blue eye color (p < 10−300)." → (rs12913832 variant, eye color phenotype, GWAS association).
**Mechanistic Description**: "Overexpression of HER2 drives proliferation in breast cancer by activating the PI3K/AKT pathway." → (ERBB2/HER2, Breast Cancer, Driver).
**Negative Association**: "No significant association between APOE ε4 and Parkinson's disease was found in this cohort." → Negative/null finding — critical to prevent false positive database entries.
**Speculative/Hedged**: "These data suggest LRRK2 may be involved in sporadic Parkinson's disease." → Uncertain evidence — must be distinguished from confirmed associations.
**Entity Recognition Challenges**
- **Gene Name Ambiguity**: "CAT" is the gene catalase but also an English word. "MET" is the hepatocyte growth factor receptor but also a preposition.
- **Synonym Explosion**: TP53 = p53 = tumor protein 53 = TRP53 = FLJ92943 — gene entities have dozens of aliases.
- **Variant Notation**: "p.Glu342Lys," "rs28931570," "c.1024G>A" — three notations for the same SERPINA1 variant causing alpha-1 antitrypsin deficiency.
- **Disease Ambiguity**: "Cancer," "tumor," "malignancy," "neoplasm," "carcinoma" — hierarchical disease terms requiring OMIM/DOID normalization.
**Performance Results**
| Benchmark | Model | F1 |
|-----------|-------|-----|
| NCBI Disease (gene-disease) | BioLinkBERT | 87.3% |
| BioRED gene-disease relation | PubMedBERT | 78.4% |
| DisGeNET auto-extraction | Curated ensemble | 82.1% |
| Variant-disease (ClinVar mining) | BioBERT | 81.7% |
**Clinical Applications**
**Rare Disease Diagnosis**: When a patient's whole-exome sequencing reveals a variant of uncertain significance (VUS) in a poorly characterized gene, automated gene-disease extraction can find publications describing similar variants in similar phenotypes.
**Cancer Driver Analysis**: Mining literature for somatic mutation-cancer associations populates COSMIC and OncoKB — databases used by oncologists to interpret tumor sequencing reports.
**Drug Target Validation**: Gene-disease association strength (number of independent studies, effect sizes) is a key predictor of the probability that targeting the gene will treat the disease.
**Pharmacogenomics**: CYP2D6, CYP2C9, and other pharmacogene-drug interaction associations extracted from literature directly inform FDA drug labeling with genotype-guided dosing recommendations.
Gene-Disease Association Extraction is **the genetic medicine knowledge engine** — systematically mining millions of publications to build the gene-disease knowledge base that connects genomic variants to clinical phenotypes, enabling precision medicine applications from rare disease diagnosis to oncology treatment selection.